News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
815,381 Results
Type
Article (74321)
Company Profile (644)
Press Release (740416)
Multimedia
Podcasts (121)
Webinars (13)
Section
Business (227445)
Career Advice (3718)
Deals (39303)
Drug Delivery (129)
Drug Development (89343)
Employer Resources (198)
FDA (17842)
Job Trends (17127)
News (387708)
Policy (38759)
Tag
2024 BioCapital Digital (20)
2024 BioForest Digital (16)
2024 BioForest Standard (1)
2024 BioMidwest Digital (14)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (19)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (20)
2024 Biotech Beach Digital (15)
2024 Biotech Beach Standard (9)
2024 Genetown Digital (10)
2024 Genetown Standard (11)
2024 Lone Star Bio Digital (17)
2024 Pharm Country Digital (13)
2024 Pharm Country Standard (6)
2025 BioForest Digital (6)
2025 Lone Star Bio Digital (10)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (2)
Academia (2998)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (90)
Alliances (55945)
ALS (97)
Alzheimer's disease (1490)
Antibody-drug conjugate (ADC) (144)
Approvals (17806)
Artificial intelligence (286)
Autoimmune disease (27)
Automation (15)
Bankruptcy (403)
Best Places to Work (12633)
BIOSECURE Act (21)
Biosimilars (118)
Biotechnology (440)
Bladder cancer (67)
Brain cancer (31)
Breast cancer (284)
Cancer (2246)
Cardiovascular disease (195)
Career advice (3165)
Career pathing (33)
CAR-T (164)
Cell therapy (457)
Cervical cancer (21)
Clinical research (72041)
Collaboration (869)
Compensation (526)
Complete response letters (30)
COVID-19 (2859)
CRISPR (45)
C-suite (245)
Cystic fibrosis (107)
Data (2107)
Decentralized trials (2)
Denatured (41)
Depression (51)
Diabetes (283)
Diagnostics (6894)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (129)
Drug pricing (123)
Drug shortages (33)
Duchenne muscular dystrophy (99)
Earnings (93589)
Editorial (43)
Employer branding (25)
Employer resources (167)
Events (128325)
Executive appointments (738)
FDA (19092)
Featured Employer (64)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (776)
Gene editing (115)
Generative AI (28)
Gene therapy (336)
GLP-1 (839)
Government (5097)
Grass and pollen (5)
Guidances (51)
Healthcare (20866)
Huntington's disease (25)
IgA nephropathy (28)
Immunology and inflammation (139)
Indications (27)
Infectious disease (3017)
Inflammatory bowel disease (149)
Inflation Reduction Act (11)
Influenza (55)
Intellectual property (95)
Interviews (726)
IPO (17731)
IRA (51)
Job creations (4987)
Job search strategy (2593)
Kidney cancer (10)
Labor market (40)
Layoffs (545)
Leadership (21)
Legal (9910)
Liver cancer (78)
Lung cancer (326)
Lymphoma (144)
Machine learning (5)
Management (65)
Manufacturing (320)
MASH (70)
Medical device (14583)
Medtech (14588)
Mergers & acquisitions (22084)
Metabolic disorders (757)
Multiple sclerosis (82)
NASH (23)
Neurodegenerative disease (107)
Neuropsychiatric disorders (31)
Neuroscience (2060)
NextGen: Class of 2025 (7635)
Non-profit (5075)
Northern California (2599)
Now hiring (39)
Obesity (413)
Opinion (272)
Ovarian cancer (76)
Pain (92)
Pancreatic cancer (83)
Parkinson's disease (157)
Partnered (22)
Patents (239)
Patient recruitment (103)
Peanut (51)
People (63980)
Pharmaceutical (133)
Pharmacy benefit managers (21)
Phase I (22262)
Phase II (31416)
Phase III (23701)
Pipeline (1165)
Policy (161)
Postmarket research (3256)
Preclinical (9778)
Press Release (72)
Prostate cancer (103)
Psychedelics (38)
Radiopharmaceuticals (267)
Rare diseases (420)
Real estate (7145)
Recruiting (75)
Regulatory (25986)
Reports (57)
Research institute (2654)
Resumes & cover letters (579)
Rett syndrome (4)
RNA editing (4)
RSV (50)
Schizophrenia (77)
Series A (137)
Series B (87)
Service/supplier (26)
Sickle cell disease (58)
Southern California (2255)
Special edition (18)
Spinal muscular atrophy (165)
Sponsored (33)
Startups (4194)
State (2)
Stomach cancer (16)
Supply chain (72)
Tariffs (29)
The Weekly (78)
United States (23506)
Vaccines (790)
Venture capitalists (41)
Weight loss (299)
Women's health (37)
Worklife (19)
Date
Today (34)
Last 7 days (521)
Last 30 days (2533)
Last 365 days (35467)
2025 (9945)
2024 (37898)
2023 (42567)
2022 (53926)
2021 (58723)
2020 (57663)
2019 (51302)
2018 (39084)
2017 (36830)
2016 (37739)
2015 (43730)
2014 (38413)
2013 (34388)
2012 (36287)
2011 (36403)
2010 (35833)
Location
Africa (1191)
Alabama (59)
Alaska (7)
Arizona (245)
Arkansas (14)
Asia (48551)
Australia (8355)
California (6066)
Canada (1983)
China (525)
Colorado (271)
Connecticut (288)
Delaware (144)
Europe (109626)
Florida (889)
Georgia (216)
Hawaii (1)
Idaho (63)
Illinois (589)
India (29)
Indiana (324)
Iowa (10)
Japan (154)
Kansas (108)
Kentucky (27)
Louisiana (13)
Maine (70)
Maryland (930)
Massachusetts (4688)
Michigan (240)
Minnesota (406)
Mississippi (2)
Missouri (88)
Montana (31)
Nebraska (26)
Nevada (62)
New Hampshire (68)
New Jersey (1747)
New Mexico (31)
New York (1725)
North Carolina (1088)
North Dakota (8)
Northern California (2599)
Ohio (209)
Oklahoma (15)
Oregon (45)
Pennsylvania (1346)
Puerto Rico (12)
Rhode Island (33)
South America (1564)
South Carolina (21)
South Dakota (1)
Southern California (2255)
Tennessee (102)
Texas (910)
Utah (182)
Virginia (158)
Washington D.C. (67)
Washington State (578)
West Virginia (3)
Wisconsin (63)
815,381 Results for "otsuka pharmaceutical co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Otsuka to Terminate Development of AVP-786
Otsuka Pharmaceutical Co., Ltd. and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc. announce termination of development of the novel compound AVP-786, which was in development as a potential treatment for patients with agitation associated with dementia due to Alzheimer’s disease.
May 22, 2024
·
2 min read
Biotech Beach
Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
Ionis Pharmaceuticals, Inc. announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. under which Otsuka obtains exclusive rights across the Asia-Pacific region for donidalorsen, an investigational RNA-targeted prophylactic medicine for hereditary angioedema.
June 18, 2024
·
5 min read
Press Releases
Otsuka Files Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
April 1, 2025
·
9 min read
Business
Otsuka and Lundbeck Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination With Sertraline for the Treatment of Adults With Post-Traumatic Stress Disorder (PTSD)
Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announce the U.S. Food and Drug Administration (FDA) has determined that the supplemental New Drug Application (sNDA) for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD) is sufficiently complete to permit a substantive review. The FDA has assigned the application for a Prescription Drug User Fee Act (PDUFA) target action date of February 8, 2025.
June 25, 2024
·
19 min read
Business
Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn
Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and Click Therapeutics, Inc., (Click) announce that the U.S. Food and Drug Administration (FDA) has cleared Rejoyn.
April 1, 2024
·
12 min read
Press Releases
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
March 25, 2025
·
5 min read
Press Releases
WORK Medical Technology Group LTD Announces Strategic Partnership with Shanghai Chartwell Medical Device Co., Ltd.
March 3, 2025
·
5 min read
Drug Development
Otsuka Announces Phase 3 Topline Results of AVP-786 in the Treatment of Agitation Associated With Dementia Due to Alzheimer’s Disease
Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) and our parent company Otsuka Pharmaceutical, Co. Ltd. (Otsuka) announce topline results of the phase 3 clinical trial of AVP-786 in the treatment of agitation associated with dementia due to Alzheimer’s disease (Trial 17-AVP-786-305; NCT03393520).
February 12, 2024
·
4 min read
Business
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen, an investigational prophylactic treatment for hereditary angioedema (HAE).
December 18, 2023
·
5 min read
Drug Development
Otsuka and Lundbeck Present Results from Three Clinical Trials of Brexpiprazole in Combination with Sertraline for the Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults
Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck Pharmaceuticals LLC (Lundbeck) today presented results from the Phase II (Trial 061) and Phase III trials (Trial 071 and 072) evaluating the safety and efficacy of brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD).
May 28, 2024
·
20 min read
1 of 81,539
Next
